Scholarlink

Background <p>Major depressive disorder (MDD) involves neuroinflammation and dysregulation of non-coding RNAs ; however, effective targeted therapies remain limited. This study investigated the antidepressant effects and molecular mechanisms of the flavonoid schaftoside.</p> Methods <p>Depression-like behaviors were assessed using sucrose preference test, open field test, and elevated plus maze test. Levels of the proinflammatory cytokines (TNF-α, IL-1β, IL-6) were measured in hippocampal tissue. Whole-transcriptome sequencing were performed to identify differentially expressed mRNAs, miRNAs and circRNAs followed by construction of a competing endogenous RNA (ceRNA) network. The interaction between circ_0001470 and miR-183-5p was validated through co-transfection and dual-luciferase assays. MeRIP-seq was conducted on mouse hippocampus tissue, and an LPS-induced inflammatory model was established in BV-2 cells. m6A methylation levels of relevant genes were assessed using m6A-IP-qPCR.</p> Results <p>Schaftoside treatment significantly ameliorated depressive-like behaviors in CUMS-induced mice and reduced hippocampal levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6. Transcriptome identified 421 mRNAs, 29 miRNAs, and 51 circRNAs were altered in response to schaftoside, with the MAPK signaling pathway emerging as a key regulatory pathway. CeRNA and cellular analysis and cellular assay confirmed that circ_0001470 functions as a sponge for miR-183-5p, thereby regulating its downstream target MAP3K1. In LPS-treated BV-2 cells, both METTL3 expression and m6A methylation of circ_0001470 were increased. Treatment with the METTL3 inhibitor STM2457 effectively suppressed METTL3 expression and reduced m6A levels on circ_0001470. Schaftoside was found to inhibits METTL3, decrease m6A modification of circ_0001470, and block subsequent inflammatory cascades.</p> Conclusions <p>These findings demonstrated for the first time that schaftoside alleviates neuroinflammation by regulating METTL3-mediated m6A modification of circ_0001470, which in turn sponges miR-183-5p to modulate MAP3K1 expression. This work provide new insights into potential therapeutic strategies for MDD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schaftoside inhibits neuroinflammation and exerts antidepressant effects through METTL3-mediated m6A modification of circ_0001470 sponging miR-183-5p to regulate MAP3K1 expression

  • 期刊论文

  • 发表日期：

    2026年3月23日

查看全文
  • Haohao Wang,
  • Jinxiang Wu,
  • Keren Ma,
  • Ting Su,
  • Qiyan Lin,
  • Hongyan Zhang,
  • Teng Ma,
  • Pan Wang,
  • Dong Liu

摘要

Background

Major depressive disorder (MDD) involves neuroinflammation and dysregulation of non-coding RNAs ; however, effective targeted therapies remain limited. This study investigated the antidepressant effects and molecular mechanisms of the flavonoid schaftoside.

Methods

Depression-like behaviors were assessed using sucrose preference test, open field test, and elevated plus maze test. Levels of the proinflammatory cytokines (TNF-α, IL-1β, IL-6) were measured in hippocampal tissue. Whole-transcriptome sequencing were performed to identify differentially expressed mRNAs, miRNAs and circRNAs followed by construction of a competing endogenous RNA (ceRNA) network. The interaction between circ_0001470 and miR-183-5p was validated through co-transfection and dual-luciferase assays. MeRIP-seq was conducted on mouse hippocampus tissue, and an LPS-induced inflammatory model was established in BV-2 cells. m6A methylation levels of relevant genes were assessed using m6A-IP-qPCR.

Results

Schaftoside treatment significantly ameliorated depressive-like behaviors in CUMS-induced mice and reduced hippocampal levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6. Transcriptome identified 421 mRNAs, 29 miRNAs, and 51 circRNAs were altered in response to schaftoside, with the MAPK signaling pathway emerging as a key regulatory pathway. CeRNA and cellular analysis and cellular assay confirmed that circ_0001470 functions as a sponge for miR-183-5p, thereby regulating its downstream target MAP3K1. In LPS-treated BV-2 cells, both METTL3 expression and m6A methylation of circ_0001470 were increased. Treatment with the METTL3 inhibitor STM2457 effectively suppressed METTL3 expression and reduced m6A levels on circ_0001470. Schaftoside was found to inhibits METTL3, decrease m6A modification of circ_0001470, and block subsequent inflammatory cascades.

Conclusions

These findings demonstrated for the first time that schaftoside alleviates neuroinflammation by regulating METTL3-mediated m6A modification of circ_0001470, which in turn sponges miR-183-5p to modulate MAP3K1 expression. This work provide new insights into potential therapeutic strategies for MDD.